Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Portfolio Pulse from
Heron Therapeutics (HRTX) reported a Q3 loss of $0.03 per share, matching the Zacks Consensus Estimate, but missed revenue estimates. This is an improvement from a $0.17 per share loss a year ago.
November 12, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Heron Therapeutics reported a Q3 loss of $0.03 per share, in line with expectations, but missed revenue estimates. This is an improvement from last year's $0.17 per share loss.
The company's earnings per share met expectations, which is a positive sign, but missing revenue estimates could negatively impact investor sentiment. The improvement from last year's loss is a positive trend, but the revenue miss is likely to weigh more heavily in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100